{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T09:47:01Z","timestamp":1788515221154,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"the National Key Research and Development Program of China Grant","award":["2016YFC0901500"],"award-info":[{"award-number":["2016YFC0901500"]}]},{"name":"Center for Rare Diseases Research, Chinese Academy of Medical Sciences, Beijing, China","award":["2016ZX310174-4"],"award-info":[{"award-number":["2016ZX310174-4"]}]},{"name":"Grant from CAMS Innovation Fund for Medical Sciences","award":["2016-I2M-1-002"],"award-info":[{"award-number":["2016-I2M-1-002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s10067-019-04784-y","type":"journal-article","created":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T07:03:11Z","timestamp":1573542191000},"page":"813-821","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The Chinese herb Tripterygium wilfordii Hook F for the treatment of systemic sclerosis-associated interstitial lung disease: data from a Chinese EUSTAR Center"],"prefix":"10.1007","volume":"39","author":[{"given":"Luwei","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuliang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengtao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,12]]},"reference":[{"key":"4784_CR1","first-page":"455","volume":"7","author":"D Xu","year":"2011","unstructured":"Xu D, Li MT, Hou Y et al (2011) Preliminary analysis of Chinese patients with systemic sclerosis. Chin J Rheumatol 7:455\u2013459","journal-title":"Chin J Rheumatol"},{"issue":"6","key":"4784_CR2","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s00296-016-3636-7","volume":"37","author":"R Giacomelli","year":"2017","unstructured":"Giacomelli R, Liakouli V, Berardicurti O et al (2017) Interstitial lung disease in systemic sclerosis: current and future treatment. Rheumatol Int 37(6):853\u2013863","journal-title":"Rheumatol Int"},{"issue":"11","key":"4784_CR3","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.2174\/138161212799504704","volume":"18","author":"T Dimitroulas","year":"2012","unstructured":"Dimitroulas T, Giannakoulas G, Karvounis H, Settas L, Kitas GD (2012) Systemic sclerosis-related pulmonary hypertension: unique characteristics and future treatment targets. Curr Pharm Des 18(11):1457\u20131464","journal-title":"Curr Pharm Des"},{"issue":"7","key":"4784_CR4","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1136\/ard.2006.066068","volume":"66","author":"VD Steen","year":"2007","unstructured":"Steen VD, Medsger TA (2007) Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 66(7):940\u2013944","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"4784_CR5","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin DP, Roth MD, Clements PJ et al (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4(9):708\u2013719","journal-title":"Lancet Respir Med"},{"issue":"8","key":"4784_CR6","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1007\/s00296-011-1967-y","volume":"32","author":"H Poormoghim","year":"2012","unstructured":"Poormoghim H, Moradi Lakeh M, Mohammadipour M, Sodagari F, Toofaninjed N (2012) Cyclophosphamide for scleroderma lung disease: a systematic review and meta-analysis. Rheumatol Int 32(8):2431\u20132444","journal-title":"Rheumatol Int"},{"issue":"6","key":"4784_CR7","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1136\/ard.2006.062901","volume":"66","author":"UA Walker","year":"2007","unstructured":"Walker UA, Tyndall A, Czirjak L et al (2007) Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 66(6):754\u2013763","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"4784_CR8","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/00005792-200203000-00004","volume":"81","author":"C Ferri","year":"2002","unstructured":"Ferri C, Valentini G, Cozzi F et al (2002) Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 81(2):139\u2013153","journal-title":"Medicine (Baltimore)"},{"issue":"25","key":"4784_CR9","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1056\/NEJMoa055120","volume":"354","author":"DP Tashkin","year":"2006","unstructured":"Tashkin DP, Elashoff R, Clements PJ et al (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354(25):2655\u20132666","journal-title":"N Engl J Med"},{"issue":"5","key":"4784_CR10","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.amjmed.2010.12.009","volume":"124","author":"DE Furst","year":"2011","unstructured":"Furst DE, Tseng CH, Clements PJ et al (2011) Adverse events during the Scleroderma Lung Study. Am J Med 124(5):459\u2013467","journal-title":"Am J Med"},{"issue":"25","key":"4784_CR11","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1056\/NEJMe068095","volume":"354","author":"FJ Martinez","year":"2006","unstructured":"Martinez FJ, McCune WJ (2006) Cyclophosphamide for scleroderma lung disease. N Engl J Med 354(25):2707\u20132709","journal-title":"N Engl J Med"},{"issue":"6","key":"4784_CR12","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1136\/annrheumdis-2013-204807","volume":"74","author":"QW Lv","year":"2015","unstructured":"Lv QW, Zhang W, Shi Q et al (2015) Comparison of Tripterygium wilfordii Hook F with methotrexate in the treatment of active rheumatoid arthritis (TRIFRA): a randomised, controlled clinical trial. Ann Rheum Dis 74(6):1078\u20131086","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"4784_CR13","doi-asserted-by":"publisher","first-page":"e0133724","DOI":"10.1371\/journal.pone.0133724","volume":"10","author":"Q Hu","year":"2015","unstructured":"Hu Q, Yang C, Wang Q, Zeng H, Qin W (2015) Demethylzeylasteral (T-96) Treatment ameliorates mice lupus nephritis accompanied by inhibiting activation of NF-kappaB pathway. PLoS One 10(7):e0133724","journal-title":"PLoS One"},{"issue":"3","key":"4784_CR14","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/j.1365-2125.2012.04221.x","volume":"74","author":"R Han","year":"2012","unstructured":"Han R, Rostami-Yazdi M, Gerdes S, Mrowietz U (2012) Triptolide in the treatment of psoriasis and other immune-mediated inflammatory diseases. Br J Clin Pharmacol 74(3):424\u2013436","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"4784_CR15","first-page":"L830","volume":"298","author":"GW Hoyle","year":"2010","unstructured":"Hoyle GW, Hoyle CI, Chen J, Chang W, Williams RW, Rando RJ (2010) Identification of triptolide, a natural diterpenoid compound, as an inhibitor of lung inflammation. Am J Phys Lung Cell Mol Phys 298(6):L830\u2013L836","journal-title":"Am J Phys Lung Cell Mol Phys"},{"key":"4784_CR16","first-page":"2623085","volume":"2018","author":"M Lv","year":"2018","unstructured":"Lv M, Deng J, Tang N, Zeng Y, Lu C (2018) Efficacy and safety of Tripterygium Wilfordii Hook F on psoriasis vulgaris: a systematic review and meta-analysis of randomized controlled trials. Evid Based Complement Alternat Med 2018:2623085","journal-title":"Evid Based Complement Alternat Med"},{"issue":"9","key":"4784_CR17","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1002\/art.20459","volume":"50","author":"B Wang","year":"2004","unstructured":"Wang B, Ma L, Tao X, Lipsky PE (2004) Triptolide, an active component of the Chinese herbal remedy Tripterygium wilfordii Hook F, inhibits production of nitric oxide by decreasing inducible nitric oxide synthase gene transcription. Arthritis Rheum 50(9):2995\u20132303","journal-title":"Arthritis Rheum"},{"issue":"11","key":"4784_CR18","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J et al (2013) 2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative. Arthritis Rheum 65(11):2737\u20132747","journal-title":"Arthritis Rheum"},{"issue":"5","key":"4784_CR19","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/art.1780230510","volume":"23","author":"AT Masi","year":"1980","unstructured":"Masi AT, Rodnan GP, Medsger TA (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 23(5):581\u2013590","journal-title":"Arthritis Rheum"},{"issue":"2","key":"4784_CR20","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s12016-009-8194-2","volume":"40","author":"J Le Pavec","year":"2011","unstructured":"Le Pavec J, Launay D, Mathai SC, Hassoun PM, Humbert M (2011) Scleroderma lung disease. Clin Rev Allergy Immunol 40(2):104\u2013116","journal-title":"Clin Rev Allergy Immunol"},{"issue":"11","key":"4784_CR21","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1002\/art.40560","volume":"70","author":"A Fernandez-Codina","year":"2018","unstructured":"Fernandez-Codina A, Walker KM, Pope JE (2018) Treatment algorithms for systemic sclerosis according to experts. Arthritis Rheum 70(11):1820\u20131828","journal-title":"Arthritis Rheum"},{"key":"4784_CR22","doi-asserted-by":"crossref","unstructured":"Antoniu SA (2007) Cyclophosphamide for scleroderma interstitial lung disease. Expert Opin Investig Drugs 16(3): 393-395.\u00a0","DOI":"10.1517\/13543784.16.3.393"},{"issue":"6","key":"4784_CR23","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1586\/1744666X.2.6.849","volume":"2","author":"S Schulz","year":"2006","unstructured":"Schulz S, Bischoff L, Michel D, Derk CT (2006) Scleroderma lung disease: treatment with cyclophosphamide. Expert Rev Clin Immunol 2(6):849\u2013852","journal-title":"Expert Rev Clin Immunol"},{"issue":"12","key":"4784_CR24","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1136\/ard.2007.069518","volume":"66","author":"PJ Clements","year":"2007","unstructured":"Clements PJ, Roth MD, Elashoff R et al (2007) Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. Ann Rheum Dis 66(12):1641\u20131647","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"4784_CR25","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1093\/rheumatology\/key151","volume":"58","author":"D Khanna","year":"2018","unstructured":"Khanna D, Tashkin DP, Denton CP, Lubell MW, Vazquez-Mateo C, Wax S (2018) Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease. Rheumatology (Oxford) 58(4):567\u2013579","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"4784_CR26","doi-asserted-by":"publisher","first-page":"234","DOI":"10.5301\/jsrd.5000205","volume":"1","author":"D Launay","year":"2016","unstructured":"Launay D, Buchdahl AL, Berezn\u00e9 A, Hatron PY, Hachulla E, Mouthon L (2016) Mycophenolate mofetil following cyclophosphamide in worsening systemic sclerosis-associated interstitial lung disease. J Scleroderma Relat Disord 1(2):234\u2013240","journal-title":"J Scleroderma Relat Disord"},{"issue":"3","key":"4784_CR27","first-page":"831","volume":"151","author":"DJ Abraham","year":"1997","unstructured":"Abraham DJ, Vancheeswaran R, Dashwood MR et al (1997) Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol 151(3):831\u2013841","journal-title":"Am J Pathol"},{"issue":"1","key":"4784_CR28","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ajpath.2012.09.007","volume":"182","author":"S Bhattacharyya","year":"2013","unstructured":"Bhattacharyya S, Kelley K, Melichian DS et al (2013) Toll-like receptor 4 signaling augments transforming growth factor-beta responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma. Am J Pathol 182(1):192\u2013205","journal-title":"Am J Pathol"},{"issue":"4","key":"4784_CR29","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1007\/s10753-014-9858-5","volume":"37","author":"D Wei","year":"2014","unstructured":"Wei D, Huang Z (2014) Anti-inflammatory effects of triptolide in LPS-induced acute lung injury in mice. Inflammation 37(4):1307\u20131316","journal-title":"Inflammation"},{"issue":"1","key":"4784_CR30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.phytochem.2010.10.015","volume":"72","author":"SK Law","year":"2011","unstructured":"Law SK, Simmons MP, Techen N et al (2011) Molecular analyses of the Chinese herb Leigongteng (Tripterygium wilfordii Hook.f.). Phytochemistry 72(1):21\u201326","journal-title":"Phytochemistry"},{"issue":"6","key":"4784_CR31","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.phytochem.2006.11.029","volume":"68","author":"AM Brinker","year":"2007","unstructured":"Brinker AM, Ma J, Lipsky PE, Raskin I (2007) Medicinal chemistry and pharmacology of genus Tripterygium (Celastraceae). Phytochemistry 68(6):732\u2013766","journal-title":"Phytochemistry"},{"key":"4784_CR32","doi-asserted-by":"publisher","first-page":"348450","DOI":"10.1155\/2012\/348450","volume":"2012","author":"W Lei","year":"2012","unstructured":"Lei W, Jian L (2012) Changes of CD4(+) CD25(+) Regulatory T Cells, FoxP3 in adjuvant arthritis rats with damage of pulmonary function and effects of tripterygium glycosides tablet. Int J Rheumatol 2012:348450","journal-title":"Int J Rheumatol"},{"issue":"1","key":"4784_CR33","first-page":"22","volume":"24","author":"YL Shi","year":"2003","unstructured":"Shi YL, Bai JP, Wang WP (2003) Ion-channels in human sperm membrane and contraceptive mechanisms of male antifertility compounds derived from Chinese traditional medicine. Acta Pharmacol Sin 24(1):22\u201330","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"4784_CR34","first-page":"50","volume":"21","author":"J Gu","year":"2001","unstructured":"Gu J, Zhu C, Wang W, Wang L (2001) The effects of Lei Gong Teng on reproductive hormones. J Tradit Chin Med 21(1):50\u201351","journal-title":"J Tradit Chin Med"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04784-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-019-04784-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04784-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T00:57:12Z","timestamp":1605056232000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-019-04784-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,12]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["4784"],"URL":"https:\/\/doi.org\/10.1007\/s10067-019-04784-y","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,12]]},"assertion":[{"value":"19 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the Medical Ethics Committee of PUMCH (Beijing, China). Informed consent was not relevant as it was a retrospective study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}